New in CME Courses: Navigating the Challenges of Prescribing PCSK9 Inhibitors in Patients with Persistent Elevated LDL-C

 Target audience:  Lipidologists, endocrinologists, and cardiologists, nurse practitioners, physician assistants, registered dietitians, advanced practice registered nurses, registered nurses, and pharmacists who are members of the NLA, as well as a national cohort of providers who manage patients with high LDL cholesterolemia

The goal of this activity is to provide evidence-based support and a clinical rationale for the use of PCSK9 inhibitors (PSCK9Is) in certain patients with hypercholesterolemia. Interactive case challenges will be used to demonstrate patient eligibility and required documentation for payers in eligible patients using clinical trial and tolerability data.

James Underberg, MS, MD, FACPM, FACP, FASH, FASPC, FNLA, clinical assistant professor, department of Medicine, division of General Internal Medicine, NYU Medical School in New York, New York; Mary Katherine Cheeley, PharmD, BCPS, CLS, clinical pharmacist specialist in Grady Health System in Atlanta, Georgia; and Winston Wong, PharmD, president of W-Squared Group and former associate vice president of Pharmacy Management CareFirst BlueCross BlueShield in Longboat Key, Florida, will discuss barriers to the prescribing of PCSK9Is and methods for overcoming these barriers. Tools and resources that can be used to facilitate access to this important therapeutic option for the treatment of elevated LDL-C are also provided.

This activity Navigating the Challenges of Prescribing PCSK9 Inhibitors in Patients with Persistent Elevated LDL-C, offers 1.0 AMA PRA Category 1 Credit™, 1 ACPE contact hour, 1 ANCC contact hour, and 1 CDR continuing professional education unit.

Click here to start this activity!